Suspension Of China Drug Track And Trace Platform Prompts Spat
This article was originally published in SRA
The China Food and Drug Administration is inviting feedback on how to change the way it monitors drugs in the supply chain after temporarily suspending its electronic system for monitoring and tracking drug products (Drug PIATS), which is operated by Hong Kong-listed Alibaba Health Information Technology.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.